On March 25, 2019 Ascentage Pharma, globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases, reported that research results of its pipeline of small molecule therapeutics will be presented at the 2019 American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting in Atlanta, March 29-April 3, 2019 (Press release, Ascentage Pharma, MAR 25, 2019, View Source [SID1234534612]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
AACR abstracts include:
Title: Predicting Drug Sensitivity to A Novel BCL-2 and BCL-xL Dual Inhibitor In Solid Tumor PDX TrialsSession Title: BCL-2 Family ProteinsSession Date and Time: Monday, April 1, 2019 1:00 PM – 5:00 PM EDTPoster Number: 2503
Title: MDM2 Inhibitor APG-115 Synergizes With CDK4/6 Inhibitors In A Patient Derived Xenograft Model of Dedifferentiated LiposarcomaSession Title: Credentialing of Molecular TargetsSession Date and Time: Monday, April 1, 2019 8:00 AM – 12:00 PM EDTPoster Number: 1253
Title: Activation of P53 In the Tumor Microenvironment by MDM2 Inhibitor APG-115 Synergizes With PD-1 Blockade Independently of P53 Status of Tumor CellsSession Title: Combination Immunotherapies 2 Session Date and Time: Tuesday, April 2, 2019 8:00 AM – 12:00 PM EDTPoster Number: 3192
Title: BCL-2 Selective Inhibitor APG-2575 Synergizes with BTK Inhibitor in Preclinical Xenograft Models of Follicular Lymphoma and diffuse Large B-cell LymphomaSession Title: Apoptosis, Necrosis, and Cancer Cell SurvivalSession Date and Time: Monday, April 1, 2019 1:00 PM – 5:00 PM EDTPoster Number: 2058
Title: Synergistic Effect of BCL-2 Inhibitor APG-2575 and CDK9 Inhibitor in Acute Myeloid Leukemia and DLBCL Preclinical Tumor ModelsSession Title: Novel Antitumor Agents 1Session Date and Time: Tuesday, April 2, 2019 8:00 AM – 12:00 PM EDTPoster Number: 3068
Title: FAK Blockade Enhances Antitumor Effect of BTK Inhibitor In Esophageal Squamous Cell Carcinoma via EGFR-ERK-Akt Pathway InhibitionSession Title: Combination Approaches to Novel TherapiesSession Date and Time: Sunday, March 31, 2019 1:00 PM – 5:00 PM EDTPoster Number: 309
Title: A Novel Bcl-2/Bcl-XL Inhibitor APG-1252-12A as A Potential Therapeutic Strategy for Gastric CarcinomaSession Title: Apoptosis, Necrosis, and Cancer Cell SurvivalSession Date and Time: Monday, April 1, 2019 1:00 PM – 5:00 PM EDTPoster Number:2054
Title: FAK Inhibition Reduces Tumor Infiltration of Tregs Via Restricting CCL5 Release and Boosts the Present Therapeutic Regimen for BRAFV600E -mutated Colorectal CarcinomaSession Title: Immunomodulation by Chemotherapy and Targeted AgentsSession Date and Time: Tuesday, April 2, 2019 1:00 PM – 5:00 PM EDTPoster Number: 3958
Title: Novel FAK/ALK/ROS1 Inhibitor APG-2449 Synergizes with Osimertinib in Preclinical Xenograft Models of EGFR-mutant NSCLCSession Title: Tyrosine Kinase and Phosphatase Inhibitors 2Session Date and Time: Monday, April 1 2019 1:00 PM – 5:00 PM EDTPoster Number: 2204